It is reported that CHI3L2 acts as potent monocyte chemoattractant and angiogenic stimulus promoting breast cancer metastasis during neoadjuvant chemotherapy and expectedly serves as novel target for anti-angiogenic therapy in breast cancer52. This evidence concerns the gene CHI3L2 and breast carcinoma.